LogoFDA 510(k) Search
Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K161867
    Device Name
    On Call Pro Blood Glucose Monitoring System
    Manufacturer
    ACON LABORATORIES
    Date Cleared
    2016-08-05

    (29 days)

    Product Code
    NBW,CGA
    Regulation Number
    862.1345
    Type
    Special
    Panel
    Clinical Chemistry
    Reference & Predicate Devices
    N/A
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The On Call Pro Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood from the fingertip, forearm and palm. The On Call Pro Blood Glucose Monitoring System is intended for multiple patient use by health care professionals in health care facilities as an aid in monitoring the effectiveness of diabetes control programs. The system should only be used with single-use, auto-disabling lancing devices.

    The On call Pro Blood Glucose Monitoring System is not intended for the diagnosis of or screening for diabetes mellitus, nor intended for use on neonates. Alternative site testing (AST) should only be done during steady-state times (when glucose is not changing rapidly).

    The On Call Pro Blood Glucose Test Strips are used with the On Call Pro Blood Glucose Meter in the quantitative measurement of glucose in capillary blood from the fingertip, forearm and palm.

    Device Description

    Not Found

    AI/ML Overview

    The provided document is a 510(k) clearance letter for a medical device (On Call Pro Blood Glucose Monitoring System) and its "Indications for Use" statement. It does not contain information about the detailed acceptance criteria and study results, sample sizes, expert qualifications, or ground truth establishment relevant to the performance of the device itself.

    The document states: "We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976..." This indicates that the device has been cleared based on its substantial equivalence to a predicate device, not necessarily on a new clinical study demonstrating specific performance metrics against an acceptance criterion in the level of detail requested.

    Therefore, I cannot provide the requested information based solely on the text provided. Such details are typically found in the accompanying 510(k) summary or clinical study reports, which are not included in this document.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1